The US FDA’s complete response letter for Eli Lilly and Company’s mirikizumab for ulcerative colitis cements the company’s position as the most frequent big pharma recipient of CRLs for original applications in recent years, the Pink Sheet’s US FDA Performance Tracker shows.
The 15 biggest pharma companies received CRLs for 14 new drug applications and biologics license applications from 2021 up to the 13 April 2023 mirikizumab CRL announcement
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?